Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Medical Oncology and Therapeutics 44 7897 074717

BONE MARROW RESEARCH NEWS

Spongy tissue inside a number of your bones, like your hip and thigh bones is understood as bone marrow. It consists of stem cells. These stem cells will grow into the RBC (red blood cells) which carry oxygen to the blood and throughout the body, white blood cells that battle infections and platelets is beneficial in blood coagulation . Genetics and environmental factors are the causes of bone marrow diseases. Tests include Bone marrow and blood tests for bone marrow diseases. Treatments depend upon the condition and the way severe it's . Treatment involves transfusions of blood, medicines or a transplant of bone marrow.
Researchers from Florence, Italy report on alittle , open-label study involving 26 people with moderate to severe secondary progressive MS who underwent HSCT. Most showed signs of clinical or MRI inflammatory activity within the year before the procedure. Five years after the procedure, 42% of participants were stable with no further progression of disability that was reduced to 30% 10 years after transplant. No relapses or inflammatory activity occurred on MRI scans after treatment. These results suggest that HSCT could be appropriate during a subgroup of individuals with SPMS that have significant inflammatory activity as measured by MRI. Further study in larger numbers are needed to know who among those with secondary progressive MS might enjoy HSCT.
In January 2019, a world team of researchers led by Richard K. Burt, MD (MD (going on research sabbatical late 2019 from Northwestern University, Chicago, IL) published results of the primary randomized, control trial of bone marrow somatic cell transplant (HSCT) in people with aggressive relapsing-remitting MS. They enrolled 110 people whose MS wasn't controlled by available disease-modifying therapies. There have been no deaths or life-threatening adverse events in either group. The investigators consider this study to be preliminary and recommend that further research is required to verify these findings and to work out longer-term outcomes and safety.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Get the App